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Adiponectin is a fat-derived hormone whose reduction plays central roles in obesity-linked diseases
including insulin resistance/type 2 diabetes and atherosclerosis. The cloning of Adiponectin receptors
AdipoR1 and AdipoR2 has stimulated adiponectin research, revealing pivotal roles for AdipoRs in pleiotropic
adiponectin actions, as well as some postreceptor signaling mechanisms. Adiponectin signaling has thus
become one of the major research fields in metabolism and clinical medicine. Studies on AdipoRs will further
our understanding of the role of adiponectin in obesity-linked diseases and shortened life span and may
guide the design of antidiabetic and antiaging drugs with AdipoR as a target.Background
Roles of Adipokines in Obesity-Related Diseases
The prevalence of obesity has increased dramatically in recent
years (Friedman, 2000). It is commonly associated with type 2
diabetes, dyslipidemia, and hypertension, and the coexistence
of these diseases has been termed metabolic syndrome, which
is related to atherosclerosis (Reaven, 1997; Matsuzawa, 1997).
In addition to metabolic syndrome and atherosclerosis, obesity
has been reported to be associated with a wide spectrum of
health problems such as cancer, fatty liver, and Alzheimer’s
disease.
Insulin resistance is a key feature of these diseases and is
defined as a state in which greater than normal insulin levels
are required to maintain glucose homeostasis. To compensate
for this insulin resistance, insulin secretion is increased, leading
to hyperinsulinemia. Thus, insulin resistance and hyperinsuline-
mia are seen to coexist in obesity. The reduced cellular insulin
response due to insulin resistance results in insufficient inhibition
of gluconeogenesis in the liver and decreased glucose uptake in
skeletal muscle, leading to type 2 diabetes, thereby forming ‘‘the
vicious circle.’’ In contrast, the excessive insulin levels result in
cell proliferation and increased cellular stress such as oxidative
stress and ectopic fat accumulation in vascular smooth muscle
cells, cancer cells, hepatocytes, and neuronal cells, leading
to atherosclerosis, cancer, dyslipidemia, fatty liver, and Alz-
heimer’s disease.
Before ‘‘the vicious circle’’ is formed, what is the mechanism
by which obesity first results in insulin resistance (and then
induces hyperinsulinemia)? White adipose tissue (WAT) is
a major site of energy storage and is important for energy
homeostasis: it stores energy in the form of triglycerides during
nutritional abundance and releases it as free fatty acids (FFAs)
during nutritional deprivation (Kahn, 2000; Spiegelman and Flier,
2001). While WAT provides a survival advantage in times of star-
vation, excessWAT is now linked to obesity-related health prob-
lems in the current nutritionally rich environment. Regulated by
multiple hormonal signals, nuclear hormone receptors, and the
central nervous system, WAT has been increasingly recognized
as an important endocrine organ that secretes a number of bio-
logically active ‘‘adipokines’’ (Hotamisligil et al., 1993; Zhanget al., 1994; Lazar, 2006). Some of these adipokines have been
shown to directly or indirectly affect insulin sensitivity through
modulation of insulin signaling and the molecules involved in
glucose and lipid metabolism. Of these adipokines, adiponectin
has recently attracted much attention because of its antidiabetic
and antiatherogenic effects as well as its antiproliferative effects
in cancer cells and is expected to be a therapeutic tool for dia-
betes, metabolic syndrome, cardiovascular diseases, and
cancers (Kadowaki and Yamauchi, 2005; Kadowaki et al., 2006).
Biology, Physiology, and Pathophysiology
of Adiponectin
Identification of Adiponectin
Adiponectin, also termed Acrp30 (Scherer et al., 1995), AdipoQ
(Hu et al., 1996), apM1 (Maeda et al., 1996), or GBP28 (Nakano
et al., 1996), was originally identified independently by four
groups using different approaches. The Adiponectin gene
encodes a secreted protein expressed exclusively in both WAT
and brown adipose tissue. Adiponectin has a carboxyl-terminal
globular domain and an amino-terminal collagen domain and is
structurally similar to complement 1q (Shapiro and Scherer,
1998), which belongs to a family of proteins that form character-
istic multimers (McCormack et al., 1997). In contrast to the
expression of adipokines such as tumor necrosis factor-
a (TNF-a) andMCP-1, which cause insulin resistance, adiponec-
tin expression is reduced in obese, insulin-resistant rodent
models (Hu et al., 1996). Plasma adiponectin levels have also
been reported to be reduced in obese humans (Arita et al.,
1999). Importantly, decrease in plasma adiponectin levels
preceded the onset of diabetes in obese rhesus monkey model,
in parallel with the observation of decreased insulin sensitivity
(Hotta et al., 2001).
Discovery of the Insulin-Sensitizing Action
of Adiponectin
Using DNA chips, we screened for secreted molecules in WAT,
the expressions of which were increased in small adipocytes
from insulin sensitive mice such as heterozygous peroxisome
proliferator-activated receptor g (PPARg)-deficient mice, and
we found that increased expression of adiponectin correlates
with increased insulin sensitivity in mouse models of alteredCell Metabolism 17, February 5, 2013 ª2013 Elsevier Inc. 185
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able to improve insulin resistance in KKAymice (KKmice overex-
pressing the agouti protein), as a model of the metabolic
syndrome and type 2 diabetes linked to obesity. Plasma adipo-
nectin levels were decreased in KKAy mice fed a high-fat diet
(HFD). Replenishment of adiponectin significantly ameliorated
HFD-induced insulin resistance and hypertriglyceridemia, which
led us to propose that adiponectin is an insulin-sensitizing adipo-
kine (Yamauchi et al., 2001). These data also strongly suggested
that the HFD-induced, obesity-linked decrease in adiponectin
level is causally involved in obesity-linked insulin resistance
and the metabolic syndrome. Scherer and colleagues reported
that an acute increase in the level of circulating adiponectin trig-
gers a transient decrease in basal glucose level by inhibiting both
the expression of hepatic gluconeogenic enzymes and the rate
of endogenous glucose production in both wild-type and type
2 diabetic mice, and they proposed that adiponectin sensitizes
the body to insulin, which is associated with inhibition of endog-
enous glucose production (Berg et al., 2001; Combs et al., 2001).
Lodish and colleagues reported that a proteolytic cleavage
product of adiponectin, which structurally resembles globular
adiponectin, increases fatty acid oxidation in muscle, decreases
plasma glucose, and causes weight loss in mice (Fruebis et al.,
2001).
Subsequently, the long-term effects of adiponectin on insulin
resistance in vivowere investigated through the use of adiponec-
tin transgenic mice (Yamauchi et al., 2003a; Combs et al., 2004)
or adiponectin-deficient mice (Kubota et al., 2002; Maeda et al.,
2002; Ma et al., 2002; Nawrocki et al., 2006). Adiponectin
transgenic mice showed amelioration of insulin resistance and
diabetes. Adiponectin-deficient mice showed mild insulin resis-
tance with glucose intolerance. Adiponectin-deficient mice
also exhibited other features of metabolic syndrome, such as
dyslipidemia and hypertension (Kubota et al., 2002).
Scherer and his colleagues reported that adiponectin trans-
genic mice displayed increased expression of PPARg target
genes and became morbidly obese with improvement in insulin
sensitivity (Kim et al., 2007).
Proposal of the Adiponectin Hypothesis
in Obesity-Related Diseases
Plasma adiponectin levels have also been reported to be
reduced in obese humans, particularly those with visceral
obesity, and to correlate inversely with insulin resistance (Arita
et al., 1999; Matsuzawa, 2010). Prospective and longitudinal
studies (Lindsay et al., 2002; Spranger et al., 2003) have shown
that lower adiponectin levels are associated with a higher inci-
dence of diabetes. Adiponectin has been shown to be signifi-
cantly related to the development of type 2 diabetes in Pima
Indians (Lindsay et al., 2002). Hypoadiponectinemia has also
been demonstrated to be independently associated with meta-
bolic syndrome—indeed, more strongly than are any other
inflammatory markers (Matsushita et al., 2006). Reduced plasma
adiponectin levels are also commonly observed in a variety of
states frequently associated with insulin resistance, such as
dyslipidemia (Matsushita et al., 2006), cardiovascular disease
(Matsuzawa, 2010; Pischon et al., 2004), and hypertension
(Adamczak et al., 2003).
The reduction of plasma concentrations of adiponectin is not
only closely related to disease states such as type 2 diabetes186 Cell Metabolism 17, February 5, 2013 ª2013 Elsevier Inc.and cardiovascular diseases, but is also implicated in cancer
development in human obesity. Recent clinical studies involving
several independent cohorts have demonstrated that plasma
concentrations of adiponectin are inversely correlated with the
risk of several types of cancer (Paz-Filho et al., 2011).
Plasma adiponectin levels are reduced in obesity and are even
lower in patients with hepatic steatosis or nonalcoholic steatohe-
patitis (NASH) (Belfort et al., 2006). Interestingly, there was an
inverse relationship between the reduction in hepatic fat content
and the increase in the plasma adiponectin level when patients
were treated with thiazolidinedione (TZD) (Belfort et al., 2006).
From these data, we proposed adiponectin hypothesis (Kado-
waki et al., 2006). According to this hypothesis, reduced plasma
adiponectin levels in obesity play causal roles in obesity-linked
diseases such as type 2 diabetes, cardiovascular diseases,
and NASH.
Regulation of Biosynthesis andSecretion of Adiponectin
Biosynthesis and Secretion Pathways of Adiponectin
Multimers
Adiponectin exists in a wide range of multimer complexes in
plasma and combines via its collagen domain to create 3 major
oligomeric forms: a low-molecular-weight (LMW) trimer, a
middle-molecular-weight (MMW) hexamer, and a high-molec-
ular-weight (HMW) 12- to 18-mer (Pajvani et al., 2003; Waki
et al., 2003). Importantly, HMW adiponectin has been shown to
be able to activate AMP kinase most potently (Kobayashi
et al., 2004; Hada et al., 2007).
A truncated form of adiponectin that includes the globular
domain cleaved proteolytically from full-length adiponectin has
been reported to exist in plasma, although in very small amounts
(Fruebis et al., 2001). The Adiponectin gene expressed exclu-
sively in adipocytes has been reported to be regulated by tran-
scriptional factors including C/EBPs (Saito et al., 1999), sterol
regulatory element binding protein 1c (SREBP1c) (Seo et al.,
2004), and PPARg (Maeda et al., 2001) (Figure 1). Farmer and
his colleagues reported that during adipocyte differentiation,
SirT1 levels are decreased and PPARg levels are increased,
both of which increase endoplasmic reticulum (ER) oxidoreduc-
tase Ero1-L, thereby stimulating secretion of HMW adiponectin
(Qiang et al., 2007). Scherer and his colleagues showed that
there is an abundant pool of properly folded adiponectin in
the secretory pathway through thiol-mediated retention and
that adiponectin is covalently bound to the ER chaperone
ERp44. They also showed that another ER chaperone, Ero1-
La, plays a critical role in the release of adiponectin from
ERp44 and that these chaperones play a major role in the
assembly of HMW adiponectin. They also reported that one
mechanism for increasing circulating levels of specific adiponec-
tin complexes by PPARg agonists may be selective upregulation
of rate-limiting chaperones such as ERp44 and Ero1-La (Wang
et al., 2007) (Figure 1).
Several observations support the hypothesis that HMWadipo-
nectin is the more active form of the protein and has a more rele-
vant role in insulin sensitivity and in protecting against diabetes.
First, rare mutations—G84R and G90S—in the collagen domain
are closely associated with type 2 diabetes (Waki et al., 2003).
Subjects with either of these two mutations have extremely low
levels of HMW adiponectin, although total plasma adiponectin
Figure 1. Regulatory Mechanisms of Adiponectin Multimer
Formation
The Adiponectin gene expressed exclusively in adipocytes has been reported
to be regulated by transcriptional factors, including C/EBPs, sterol regulatory
element binding protein 1c (SREBP1c), and peroxisome proliferator-activated
receptor g (PPARg). SirT1 has recently been reported to deacetylate Lys268
and Lys293 of PPARg and to cause selective PPARg modulation, leading to
upregulation of adiponectin. There is an abundant pool of properly folded
adiponectin in the secretory pathway through thiol-mediated retention, and
that adiponectin is covalently bound to the ER chaperone ERp44. Another ER
chaperone, Ero1-La, plays a critical role in the release of adiponectin from
ERp44, and that these chaperones play a major role in the assembly of HMW
adiponectin. Hyperinsulinemia, oxidative stress and inflammation observed in
obesity have been reported to reduce HMW adiponectin, whereas TZDs and
caloric restriction have been reported to increase HMW adiponectin.
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adiponectins recombinantly expressed in NIH 3T3 fibroblasts
were not able to form the HMW form of adiponectin (Waki
et al., 2003). Second, increases in the ratio of plasma HMW adi-
ponectin levels to total adiponectin levels correlate with
improvement in insulin sensitivity during treatment with an
insulin-sensitizing drug, TZD, in both mice and human diabetes,
whereas increases in total serum adiponectin levels do not show
good correlations with improvement in insulin sensitivity during
treatment with TZD (Pajvani et al., 2004). Third, the level of
plasma HMW adiponectin was reported to be associated with
parameters related to glucose homeostasis in a cohort study
(Lara-Castro et al., 2006). It is noteworthy that the ratio of plasma
HMW adiponectin to total adiponectin correlated more signifi-
cantly with glucose and insulin levels than did the total adiponec-
tin level (Lara-Castro et al., 2006), suggesting that alterations in
plasma HMW adiponectin level may be more relevant to the
prediction of insulin resistance than are total plasma adiponectin
alterations. Consistent with this, levels of total adiponectin,
HMW adiponectin, and the HMW-to-total adiponectin ratio all
inversely correlated with key features of central obesity and posi-
tively correlated with the insulin-stimulated glucose disposalrate. However, HMW adiponectin levels, not total adiponectin
levels, are primarily responsible for these relationships, suggest-
ing that measurement of the HMW adiponectin level may be
superior to measurement of total adiponectin (Fisher et al.,
2005). Using an ELISA system for selective measurement of
HMW adiponectin, we also found HMW adiponectin and the
HMW-to-total adiponectin ratio to have significantly better
power for the prediction of insulin resistance and the metabolic
syndrome in humans (Hara et al., 2006). Thus, HMW adiponectin
level may be the superior biomarker for insulin resistance, meta-
bolic syndrome, and type 2 diabetes. However, Blu¨her et al.
failed to observe the superiority of HMW over total adiponectin
in assessing metabolic variables at baseline or in response to
physical training (Blu¨her et al., 2007), suggesting that further
studies are required for clinical effectiveness and usefulness of
measuring HMW adiponectin.
Physiological and Pathophysiological Regulation
of Plasma Adiponectin
Caloric restriction/starvation/fasting have been reported to
result in upregulation of plasma adiponectin levels (Figure 1).
Accili and his colleagues indeed showed that SirT1 gain of func-
tion increases adiponectin messenger RNA (mRNA) levels,
protein levels, and both HMW and MMW adiponectin in mice
fed either a standard diet or HFD, which resulted in increased
insulin sensitivity in the liver (Banks et al., 2008). SirT1 has
recently been reported to deacetylate Lys268 and Lys293 of
PPARg and to cause selective PPARgmodulation, leading to up-
regulation of adiponectin and repression of proinflammatory
cytokines (Qiang et al., 2012). As for insulin in the regulation of
adiponectin levels, it is reported that adipocyte-specific insulin
receptor knockout mice exhibited increased adiponectin
expression levels in adipose tissue (Blu¨her et al., 2002). In this
context, it is noteworthy that subjects with mutations in the
insulin receptor, despite having themost severe degree of insulin
resistance, had elevated plasma adiponectin (Semple et al.,
2006). Moreover, Scherer and his colleagues proposed that an
increase in serum insulin levels may trigger the induction or acti-
vation of a serum reductase that triggers the dissociation of the
HMW adiponectin, leading to the transient appearance of the
lower-molecular-weight adiponectin (Pajvani et al., 2003).
In contrast to caloric restriction/starvation/fasting, obesity
results in decreased adiponectin levels viamultiple mechanisms,
including decreased levels of SirT1, hyperinsulinemia, oxidative
stress, and inflammation (Furukawa et al., 2004). Conversely,
TZDs reverse hyperinsulinemia, oxidative stress, and inflamma-
tion, thereby increasing adiponectin levels especially those of
HMWadiponectin. Moreover, TZDs directly increase the expres-
sion of adiponectin gene itself via peroxisome proliferator
response element (PPRE) (Maeda et al., 2001). Scherer et al. re-
ported that one mechanism for increasing circulating levels of
HMW adiponectin by TZDs may be selective upregulation of
rate-limiting chaperones such as ERp44 and Ero1-La (Wang
et al., 2007) (Figure 2).
There is a sexual dimorphism in the circulating levels of adipo-
nectin. Indeed, females have higher plasma adiponectin levels
than males in humans and rodents, suggesting that sexual
hormones regulate the production of adiponectin, although it is
controversial how these hormones, such as estrogen and testos-
terone, are involved in the regulation of plasma adiponectin levelCell Metabolism 17, February 5, 2013 ª2013 Elsevier Inc. 187
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Figure 2. Cloning and Functional Analysis of Adiponectin Receptors
Adiponectin receptors AdipoR1 and AdipoR2were identified by expression cloning in 2003. AdipoR1 and AdipoR2 are significantly homologous (67% amino acid
identity). AdipoR1 and AdipoR2 appear to be integral membrane proteins; the N terminus is internal and the C terminus is external—opposite to the topology of all
reported GPCRs. AdipoR1 and AdipoR2 serve as receptors for adiponectin and mediate increased AMP-activated kinase (AMPK) and PPARs activities, thereby
regulating glucose and lipid metabolism. Both Ca2+/CaMKKb and AMP/LKB1 are necessary for adiponectin-induced full AMPK activation. Adiponectin via
AdipoR1 and AdipoR2 decreased ceramide, increased sphingosine-1-phosphate (S1P), and protected from apoptosis. T-cadherin is critical for adiponectin-
mediated cardioprotection in mice. Adiponectin increases IL-6 in macrophages via activation of NF-kB through a still unidentified adiponectin receptor AdipoRX
but not AdipoR1 or AdipoR2, leading to increased IRS-2 in hepatocytes under a fasted state.
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Nevertheless, this may partly account for the fact that females
are more sensitive to insulin than are males.
Concentrations of serum adiponectin were higher in a hyper-
thyroid state than in a hypothyroid state. A strong positive corre-
lation of adiponectin with thyroid hormones has been noted.
Thus, the plasma adiponectin level is affected by multiple
factors, such as insulin (insulin signaling in adipocytes and
insulin-dependent reductase), intracellular stress in adipocytes
(inflammation and oxidative stress), other hormones (estrogen,
testosterone and thyroid hormone), sex, aging, and lifestyle.
Adiponectin Receptors AdipoR1/AdipoR2: Molecular
Structure and Their Functions
Identification and Molecular Cloning of Adiponectin
Receptors AdipoR1 and AdipoR2
Identification and molecular cloning of adiponectin receptors
AdipoR1 and AdipoR2 have opened up an avenue of funda-
mental understanding of adiponectin actions and their physio-
logical and pathophysiological significance. AdipoR1 and
AdipoR2 are significantly homologous (67% amino acid identity),
and they are structurally conserved from yeast to humans (espe-
cially in the seven transmembrane domains) (Yamauchi et al.,188 Cell Metabolism 17, February 5, 2013 ª2013 Elsevier Inc.2003b). Interestingly, the yeast homolog (YOL002c) plays a key
role in metabolic pathways that regulate lipid metabolism, such
as fatty acid oxidation (Karpichev et al., 2002). AdipoR1 is ubiq-
uitously expressed, including abundant expression in skeletal
muscle, whereas AdipoR2 is most abundantly expressed in the
mouse liver. AdipoR1 and AdipoR2 appear to be integral
membrane proteins; the N terminus is internal and the C terminus
is external—opposite to the topology of all reported G protein-
coupled receptors (GPCRs) (Yamauchi et al., 2003b) (Figure 2).
Demonstration of Pivotal Roles of AdipoR1 and AdipoR2
in Adiponectin Actions
AdipoR1and AdipoR2 have been shown to serve as the major
adiponectin receptors in vivo, since AdipoR1,AdipoR2 double-
knockout mice showed abrogation of adiponectin binding (Ya-
mauchi et al., 2007). AdipoR1 and AdipoR2 mediate metabolic
actions of adiponectin, since AdipoR1,AdipoR2 double-
knockout mice showed abrogation of glucose-lowering effects
of adiponectin. Moreover, since AdipoR1,AdipoR2 double-
knockout mice showed glucose intolerance and hyperinsuline-
mia, AdipoR1 and AdipoR2 play physiological roles in regulation
of normal glucose metabolism and insulin sensitivity. For
example, in the liver, AdipoR1 is involved in activation of AMP-
activated kinase (AMPK), and AdipoR2 is involved in activation
Figure 3. Impaired Adiponectin Action Is a Hallmark of Obesity-
Related Diseases
Decreased adiponectin effects in obesity play causal roles in the development
of obesity-related diseases such as type 2 diabetes, fatty liver, atheroscle-
rosis, cancers, and so on, in which there are two mechanisms about disturbed
adiponectin effects; one is the absolute decrease of adiponectin, and the other
is decreased adiponectin receptors AdipoR1/R2, both of which appear to
be caused, at least in part, by increased oxidative stress, inflammation, and
hyperinsulinemia in obesity.
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AdipoR1 and AdipoR2 or suppression of AdipoR1 and AdipoR2
expression supports our conclusion that AdipoR1 and AdipoR2
serve as receptors for globular and full-length adiponectin and
mediate increased AMP-activated kinase (AMPK), PPARa ligand
activities, fatty acid oxidation, and glucose uptake by adiponec-
tin (Yamauchi et al., 2007; unpublished data) (Figure 2).
Signal Transduction Mechanisms
AMPK Activation via AdipoR1. With respect to the molecular
mechanisms underlying the insulin-sensitizing action of adipo-
nectin, we found that full-length adiponectin stimulated AMPK
phosphorylation and activation in both skeletal muscle and
the liver, while globular adiponectin did so in skeletal muscle
(Yamauchi et al., 2002) (Figure 2). Blocking AMPK activation
by use of a dominant-negative mutant inhibited these effects
of full-length or globular adiponectin, indicating that stimulation
of glucose utilization and fatty acid combustion by adiponectin
occurs through activation of AMPK (Yamauchi et al., 2002).
Lodish, Ruderman, and colleagues also showed that the adipo-
nectin globular domain could enhance muscle fat oxidation and
glucose transport via AMPK activation and acetyl-CoA car-
boxylase inhibition (Tomas et al., 2002). Consistent with the
proposed roles of AMPK activation by adiponectin in the liver
(Yamauchi et al., 2002), Scherer et al. reported that in adipo-
nectin transgenic mice (Combs et al., 2004), reduced expres-
sion of gluconeogenic enzymes such as phosphoenolpyruvate
carboxylase and glucose-6-phosphatase is associated with
elevated phosphorylation of hepatic AMPK. We showed by
using LKB1 deletion that adiponectin suppresses hepatic
SREBP1c expression in an AdipoR1/LKB1/AMPK-dependent
pathway. However, by using inducible hepatic deletion of
LKB1, Birnbaum et al. reported that LKB1- and AMPK-depen-
dent and independent signaling pathways may exist in vivo
(Miller et al., 2011).PPARActivation via AdipoR2. Adiponectin activated the PPAR
pathway via AdipoR2 (Figure 2) and also increased fatty acid
combustion and energy consumption, in part via increased
molecules involved in these functions such as ACO and UCP,
respectively (Yamauchi et al., 2003b, 2007). To clarify the mech-
anisms by which adiponectin increased the expressed levels of
ACO and UCP, we measured endogenous PPARa ligands activ-
ities, because the ACO and UCP genes possess PPRE in its
promoter regions. Interestingly, adiponectin increased PPARa
ligands activities and also expression of PPARa itself (Yamauchi
et al., 2003a).
AMPK, Ca2+, Fatty Acid Combustion, Mitochondrial Biogen-
esis, Mitochondrial OXPHOS, and ROS via AdipoR1. Adiponec-
tin induces extracellular Ca2+ influx by AdipoR1, which is
necessary for the subsequent activation of Ca2+/calmodulin-
dependent protein kinase kinase b (CaMKKb), AMPK (Figure 3).
This pathway then activated SirT1, increased expression and
decreased acetylation of PPARg coactivator1a (PGC-1a), and
increased mitochondria in myocytes. In fact, muscle-specific
disruption of AdipoR1 suppressed the adiponectin-mediated
increase in intracellular Ca2+ concentration and decreased the
activation of CaMKK, AMPK, and SirT1 by adiponectin.
Suppression of AdipoR1 also resulted in decreased PGC-1a
expression and deacetylation, decreased mitochondrial content
and enzymes, decreased oxidative type I myofibers, and
decreased oxidative stress-detoxifying enzymes in skeletal
muscle that were associated with insulin resistance and
decreased exercise endurance. Decreased levels of adiponectin
and AdipoR1 in obesity may have causal roles in the mitochon-
drial dysfunction and insulin resistance seen in diabetes (Iwabu
et al., 2010).
APPL. A two-hybrid study revealed that the C-terminal extra-
cellular domain of AdipoR1 interacted with adiponectin, whereas
the N-terminal cytoplasmic domain of AdipoR1 interacted with
APPL (adaptor protein containing pleckstrin homology domain,
phosphotyrosine-binding domain, and leucine zipper motif)
(Mao et al., 2006). Moreover, it has been reported that interaction
of APPLwith AdipoR1 inmammalian cells was stimulated by adi-
ponectin binding and this interaction played important roles in
adiponectin signaling and adiponectin-mediated downstream
events such as AMPK activation, lipid oxidation, and glucose
uptake. Furthermore, these data are consistent with that the N
terminus of adiponectin receptors is internal and the C terminus
is external (Mao et al., 2006).
Ceramide Pathway. Although it was shown that AdipoR1and
AdipoR2 regulate glucose and fatty acid metabolism partly via
activation of AMPK, Ca2+, and PPARa signaling pathways, it
seems likely that additional signaling pathways also participate
at thepleiotropic actionsof adiponectin (Figure2). In fact, Scherer
and his colleagues added ceramide signaling as a pathway
involved in mediating such pleiotropic effects (Holland et al.,
2011). Interestingly, they demonstrated that adiponectin lowers
cellular ceramide levels via activation of ceramidase, which
converts ceramide to sphingosine, leading to reduced hepatic
ceramide levels and improved insulin sensitivity (Figure 2).
Conversely, deficiency of adiponectin increases hepatic ceram-
ide levels, which may be implicated insulin resistance.
Adiponectin increased sphingosine 1-phosphate (S1P) and
protects from apoptotic cell death induced by either palmitateCell Metabolism 17, February 5, 2013 ª2013 Elsevier Inc. 189
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(Holland et al., 2011) (Figure 2). Because this protection is
reversed by either an inhibitor of ceramide biosynthesis or S1P
itself, it seems likely that adiponectin-induced S1P generation
protects cardiac myocytes and b cells from cell death. Most
importantly, this ceramide pathway, which appears to be acti-
vated adiponectin is totally dependent on AdipoR1/AdipoR2,
which was shown by the observations that overexpression of
adiponectin, AdipoR1, and AdipoR2, reduced hepatic ceramide
levels and improved insulin sensitivity.
AdipoR1 and AdipoR2 belong to the progesterone and adipoQ
receptor (PAQR) family. Some PAQR family members have been
reported to contain sequence homology with alkaline cerami-
dase (Holland et al., 2011). An important issue to be solved by
analyses of 3D structure of AdipoR1/AdipoR2 is whether the
ceramidase activity is intrinsic to the receptor or whether ceram-
idase is indirectly activated upon adiponectin stimulation via an
unknown mechanism.
Based upon the work of our laboratory, as well as other labo-
ratories such as Scherer’s laboratory, we would like to propose
the potential signal mechanisms downstream of AdipoR1 and
AdipoR2, which collectively lead to pleiotropic biological
actions; adiponectin appears to regulate more diverse and
complex pathways, such as ceramide and S1P downstream of
AdipoR1 and AdipoR2, in addition to those originally identified,
such as AMPK, Ca2+, and PPARa (Holland et al., 2011; Iwabu
et al., 2010; Kadowaki et al., 2006; Kadowaki and Yamauchi,
2011; Yamauchi et al., 2003b, 2007)(Figure 2).
Potential Existence of Other Receptors and Action
Mechanisms Such as T-Cadherin and Nonreceptor
Pathways
Lodish’s group reported that T-cadherin was capable of binding
adiponectin in C2C12 myoblasts and muscle; however, T-cad-
herin was not expressed in hepatocytes or the liver (Hug et al.,
2004), another important target organ (Combs et al., 2001; Ku-
bota et al., 2006; Nawrocki et al., 2006). Moreover, T-cadherin
by itself was thought to have no effect on adiponectin cellular
signaling or function, because T-cadherin is without an intracel-
lular domain. These data raised the possibility that T-cadherin
may be one of the adiponectin-binding proteins. Consistence
with this, in T-cadherin-deficient mice, adiponectin failed to
associate with cardiac tissue, and its levels dramatically
increased in the circulation. Interestingly, T-cadherin is critical
for adiponectin-mediated cardioprotection in mice (Denzel
et al., 2010) (Figure 2).
As for adiponectin-binding proteins, adiponectin was reported
to modulate inflammatory reactions via calreticulin (Takemura
et al., 2007). Walsh et al. showed that both calreticulin and
CD91 are involved in the adiponectin-mediated uptake of
apoptotic cells (Takemura et al., 2007). Moreover, Ouchi and
his colleagues reported that pretreatment with anti-calreticulin
antibodies reduced the binding of adiponectin to cardiac myo-
cytes and blocked the adiponectin-stimulated increase in Akt
activation and survival in cardiomyocytes.
The different properties of adiponectin from those of other
bioactive substances such as hormones and cytokines are
very important issues. Adiponectin is a unique bioactive
substance in sense of very high concentrations in plasma. There
are several possibilities that could explain the high concentra-190 Cell Metabolism 17, February 5, 2013 ª2013 Elsevier Inc.tions of adiponectin in plasma. One possibility is the unique
molecular structure of HMW adiponectin, which displays more-
potent bioactivities than trimer or hexamer adiponectin. Because
HMW adiponectin is thought to be composed of 18-mer or 36-
mer, it is possible that effective molar concentrations of adipo-
nectin in plasma may be substantially low as compared with
those calculated from mass concentrations.
Another possibility could be the unique action mode of adipo-
nectin, which may be different from that of other bioactive
substances. Adiponectin has been reported to bind to non-
signaling molecules such as extracellular collagens and some
adhesionmolecules in injured tissues presumably via low-affinity
high-capacity binding. It is important to clarify the potentially cy-
toprotective role of adiponectin that accumulates in injured
tissue.
Transcriptional Control of AdipoR in Physiology
and Obesity
The expression of AdipoR1/R2 in insulin target organs, such as
skeletal muscle and liver, significantly increases in fasted mice
and decreases in refedmice. Consistent with this, in vitro studies
revealed that insulin reduced the expression of AdipoR1/R2 via
the phosphoinositide 3 kinase/FoxO1-dependent pathway. The
expression levels of both AdipoR1 and AdipoR2 were signifi-
cantly decreased in the muscle and adipose tissue of insulin-
resistant ob/obmice, probably in part because of obesity-linked
hyperinsulinemia via FoxO (Tsuchida et al., 2004) (Figure 3).
Moreover, adiponectin-induced activation of AMPK was
impaired in the skeletal muscle of ob/ob mice. These data
suggest that adiponectin resistance is present in ob/ob mice,
presumably due to the decreased expression of AdipoR1 and
AdipoR2 (Tsuchida et al., 2004). Thus, obesity decreases not
only plasma adiponectin levels but also AdipoR1/R2 expression,
thereby reducing adiponectin sensitivity and leading to insulin
resistance, which in turn leads to hyperinsulinemia, creating
a ‘‘vicious cycle’’ (Tsuchida et al., 2004). Adiponectin receptor
expression in the skeletal muscle of type 2 diabetic patients
has been reported to be decreased (Civitarese et al., 2004). In
addition, a correlation has been reported between adiponectin
receptor gene expression and insulin sensitivity in nondiabetic
Mexican Americans with or without a family history of type 2 dia-
betes (Debard et al., 2004).
Biological Functions of AdipoR in Various Tissues
Suppression of NASH. Nonalcoholic steatohepatitis (NASH) is
one of the most frequent causes of liver dysfunction associated
with the dysregulation of synthesis and oxidation of fatty acids.
Plasma adiponectin levels have been reported to be reduced
in obesity and even more reduced in patients with NASH (Belfort
et al., 2006). Interestingly, there seemed to be an inverse rela-
tionship between the reduction in hepatic fat content and the
increase in the plasma adiponectin level when patients were
treated with TZD (Belfort et al., 2006). These data suggested
that low adiponectin levels may relate to the development of
NASH. Adiponectin receptors (AdipoR1/R2) are known asmodu-
lators of fatty acid metabolism in the liver. Yukawa and his
colleagues reported that after feeding a high-fat and high-
cholesterol diet to obese fa/fa Zucker rats for 8 weeks, they
develped fatty liver spontaneously with inflammation and fibro-
sis that are characteristic of NASH. The expression levels of
AdipoR1/R2 are significantly decreased in NASH (Matsunami
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and PPARa. Taken together, increased synthesis and decreased
oxidation of fatty acids by downregulation of AdipoR may
contribute to the progression of NASH (Matsunami et al., 2011)
(Figure 3).
Regulation of Inflammation: M1/M2 Macrophage Polarization.
Walsh and his colleagues reported that adiponectin promotes
macrophage polarization toward an anti-inflammatory pheno-
type (Ohashi et al., 2010). Nagy and his colleagues showed
that adiponectin potently shifted the polarization of Kupffer cells
and RAW264.7 macrophages to an M2/anti-inflammatory
phenotype in an IL-4/STAT6-dependent mechanism. M2 polari-
zation was also partially dependent on AMP-activated kinase
(Mandal et al., 2011).
Recently, it has been reported that saturated fatty acid-
induced AMPK inactivation results in decreased activation of
unc-51-like kinase-1 (ULK1), the mammalian homolog of auto-
phagy-related-1 (Atg1), leading to decreased autophagy,
thereby inducing mitochondrial ROS generation that activates
the NLRP3-ASC inflammasome, causing caspase-1, IL-1b, and
IL-18 production, which finally leads to insulin resistance (Wen
et al., 2011). It is interesting to clarify whether AMP kinase activa-
tion in macrophages by adiponectin/AdipoR1 could regulate
these pathways (Figure 3).
NF-kB Signaling Pathways: Yin and Yang Regulation. It is well
known that adiponectin suppresses inflammatory stimuli-
induced nuclear factor kB (NF-kB) activation (Ouchi et al.,
2000), which is thought to contribute considerably to the antidi-
abetic and antiatherogenic effects of adiponectin. Importantly,
PPAR and AMPK, downstream mediators of AdipoR1 and
AdipoR2, have been reported to antagonize inflammatory
responses by transrepression of NF-kB target genes, including
COX2 (Chandrasekar et al., 2008), which could account for the
anti-inflammatory effects of adiponectin, at least in part.
However, unexpectedly, adiponectin has also been reported
to activate NF-kB transcription factor under basal conditions in
a variety of cell types including C2C12 myocytes and myotubes
(Tsao et al., 2002). Adiponectin has been reported to cause
elevated expression of COX-2 by stromal cells and induce
release of prostaglandin E(2), and at the same time block fat
cell formation in long-term bone marrow cultures and inhibit
the differentiation of cloned stromal preadipocytes. As one
clue of the significance of NF-kB pathway activation by adipo-
nectin, we have shown that adiponectin increases IL-6 in macro-
phages via activation of NF-kB through a still-unidentified
adiponectin receptor AdipoRX but not AdipoR1 nor AdipoR2,
which results in activation of STAT3 in hepatocytes, leading to
increased IRS-2 under a fasted state, thereby increasing insulin
sensitivity (Awazawa et al., 2011) (Figure 2).
Researchers in this field might wish to clarify how adiponectin-
induced suppression of NF-kB activated by inflammatory stimuli
as well as adiponectin-induced mild activation of NF-kB under
a basal state coordinately maintain in vivo homeostasis (Yin
and Yang regulation).
Cardiovascular Function.Walsh et al. examined the role of adi-
ponectin in myocardial remodeling in response to acute injury.
Ischemia-reperfusion in adiponectin-deficient (APN-KO) mice
resulted in increased myocardial infarct size, myocardial
apoptosis, and TNF-a expression compared with wild-typemice. Administration of adiponectin diminished infarct size,
apoptosis, and TNF-a production in both APN-KO and wild-
type mice. They suggest that adiponectin protects the heart
from ischemia-reperfusion injury through both AMPK- and
COX-2-dependent mechanisms (Shibata et al., 2005).
Because COX-2 is also an important modulator of endothelial
function, Walsh and his colleagues investigated the possible
contribution of COX-2 to adiponectin-mediated vascular
responses in a mouse hind limb model of vascular insufficiency.
Disruption of the adiponectin-COX-2 regulatory axis in endothe-
lial cells could participate in the pathogenesis of obesity-related
vascular diseases (Ohashi et al., 2009).
Adiponectin receptors are expressed by cardiac myocytes
and heart tissue. Hyperinsulinemia related to obesity has been
reported to decrease myocardial AdipoR1 expression via PI3K/
Akt and FoxO1 pathway (Cui et al., 2012). Moreover, through
the use of RNA interference, decreased AdipoR1 has been re-
ported to result in decreased AMPK-dependent angiogenic
response (Shimano et al., 2010). These data suggested that
downregulation of adiponectin receptor pathway could be caus-
ally implicated in decreased cardiovascular function (Figure 3).
Suppression of Carcinogenesis. It has been shown that adipo-
nectin may exert antineoplastic activity in gastric, breast, esoph-
ageal, and prostate cancer cells, through suppression of tumor
proliferation and neoangiogenesis and through induction of
apoptosis. Recent clinical studies involving several independent
cohorts have demonstrated that plasma concentrations of adi-
ponectin are inversely correlated with the risk of several types
of cancer, including gastric, colorectal, breast, endometrial,
and prostate cancers (Paz-Filho et al., 2011).
In addition, the expression of adiponectin receptors has been
documented in several human cancer cell lines, such as gastric,
breast, prostate, and endometrial cancer cells (Barb et al., 2007).
An in vitro experiment using two gastric cancer cell lines, MKN-
74 and NUGC-3, showed that the expression levels of AdipoR1
and AdipoR2 were significantly decreased by transforming
growth factor-b in a dose-dependent manner (Otani et al.,
2010). In gastric cancer tissue, as compared to findings in the
normal counterparts, AdipoR1 mRNA expression tended to be
decreased and AdipoR2 expression was significantly decreased
(Ishikawa et al., 2007). In endometrial adenocarcinoma tissues,
decreased expression of adiponectin receptors is implicated in
the development, invasion, and metastasis (Yamauchi et al.,
2012). Adiponectin/AdipoRs is thought to reduce cancer risk at
least in part through amelioration of hyperinsulinemia as well
as through direct effects on tumor cells such as via inhibition of
themammalian target of the rapamycin (mTOR) pathway by acti-
vating AMP kinase (Fujisawa et al., 2008) (Figure 3).
Taken together, as shown in Figure 3, wewould like to propose
a hypothesis that impaired adiponectin action is hallmark of
obesity-related diseases. According to this hypothesis, obesity
is not only accompanied by hypoadiponectinemia, but also
decreased adiponectin receptors AdipoR1 and AdipoR2. Im-
paired adiponectin actions via AdipoR1 in muscle, liver, and
macrophages may cause type 2 diabetes and atherosclerosis.
Impaired adiponectin actions via AdipoR1 and AdipoR2 in liver
and cancer cell may cause fatty liver and cancer. Impaired adi-
ponectin actions via AdipoR2 in endothelial cell may cause
atherosclerosis.Cell Metabolism 17, February 5, 2013 ª2013 Elsevier Inc. 191
Figure 4. Strategies to Increase
Adiponectin Effects and Pathophysiological
Roles of Adiponectin/AdipoR in Obesity
There are several strategies to increase adipo-
nectin effects. One is to increase levels of adipo-
nectin itself, such as through the injection of
adiponectin. The second is use of compounds to
increase adiponectin expression. The third is to
activate AdipoRs, such as small-molecule
compounds and activating antibodies against
AdipoRs. The fourth is to increase levels of
AdipoRs. Increased activation of adiponectin and
AdipoRs pathways like exercise may have bene-
ficial effects on healthy longevity and lifestyle-
related diseases, such as type 2 diabetes,
metabolic syndrome, cardiovascular diseases,
cancers, NASH, and so on.
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tin and downregulation of adiponectin receptors can cause
a variety of obesity-related diseases.
Regulation of Life Span. Exercise has been reported to have
beneficial effects on obesity-related disorders such as type 2
diabetes and to contribute to healthy longevity. Activation of
AMPK occurs with exercise and has been proposed as
a longevity strategy for mammals. We previously demonstrated
that adiponectin also activates AMPK via AdipoR1 in skeletal
muscle, which in turn activates SirT1, implicated in longevity.
Therefore, AdipoR1 agonists and strategies to increase AdipoR1
in muscle tissues could be used as exercise mimetics and hope-
fully to extend life span.
Overexpression of human adiponectin (4- to 6-fold) in trans-
genic mice indeed results in the prevention of premature death
by a high-calorie diet (Otabe et al., 2007). It is interesting to deter-
mine whether APN-KO or AdipoR1,AdipoR2 double-knockout
mice show shortened life span. Results on whether the replen-
ishment of adiponectin or adiponectin actions could indeed
prolong the shortened life span under the HFD are awaited.
Therapeutic Strategy Targeted to the Adiponectin
Pathway
Decreased adiponectin effects in obesity have been reported to
play causal roles in the development of obesity-related diseases
such as diabetes and cardiovascular diseases.
There are several strategies to reverse reduced adiponectin
effects (Figure 4). One is to increase levels of adiponectin itself,
such as through the injection of adiponectin. As for injection of192 Cell Metabolism 17, February 5, 2013 ª2013 Elsevier Inc.adiponectin, there are many difficulties,
such as very high plasma concentra-
tions of adiponectin and HMW adipo-
nectin multimers as the highest activity
form.
The second is use of compounds to
increase adiponectin expression. The
TZDs, which also have pleiotropic effects
on cardiovascular diseases and lipid
metabolism, are known to exert its effects
partly through increasing the levels of
HMW adiponectin (Kubota et al., 2006;
Yamauchi et al., 2001). TZDs couldincrease adiponectin expression very potently; however, TZDs
also have other effects besides increasing adiponectin levels,
such as increasing body weight, retention of water, and bone
resorption. In this context, non-TZD selective PPARg agonists
such as INT 131 that increase adiponectin levels seem to be
superior to TZD, because INT131 has been reported to normalize
insulin signaling defects and increase bonemass in diet-induced
obese mice (Lee et al., 2012).
Some dietary factors, such as soy protein, fish oils, and linoleic
acid, are also suggested to increase plasma adiponectin levels,
which is consistent with the fact that intake of these factors is
thought to have a protective effect on the development of dia-
betes. In contrast, a carbohydrate-rich diet appears to decrease
plasma adiponectin levels (Pischon et al., 2005).
The third is to activate AdipoRs, such as small-molecule
compounds and activating antibodies against AdipoRs.
The fourth is to increase levels of AdipoRs. In pathophysiology,
the expression levels of adiponectin receptors are relatively low,
compounds that can increase the numbers of adiponectin
receptors are required for the full activation of AdipoRs. In this
context, PPARa activation by its agonist, Wy-14,643, upregu-
lated expression of AdipoR1 and AdipoR2 in WAT (Tsuchida
et al., 2005).
We have recently shown that chromatin immunoprecipitation
sequencing analysis together with other analyses, including the
gel-shift assay and luciferase assay, revealed a cluster of
multiple functional PPAR/RXR binding sites PPRE in the intron
1, downstream of the transcription start site of AdipoR2 (Waki
et al., 2011).
Figure 5. Translational Research Targeted to Adiponectin and AdipoRs
Combination of expression profiles in adipose tissues and epidemiological and clinical association studies between low adiponectin and diseases and functional
studies led to identification of adiponectin as a key molecule of lifestyle-related disease such as diabetes. Then, AdipoR1 and AdipoR2 were identified by
expression cloning. Disruption of AdipoR1 and AdipoR2 revealed that AdipoR1 and AdipoR2 are required for specific binding of adiponectin and glucose-
lowering effects of adiponectin, indicating that AdipoR1 and AdipoR2 are major adiponectin receptors in vivo. PPARa agonists and ARB increase AdipoR
expression. Human mutation analyses revealed that HMW adiponectin is the more active form of the protein and has a more relevant role in insulin sensitivity.
PPARg agonists and ARB increase total and HMW adiponectin. For development of methods for diagnosis, methods for specific quantification of HMW adi-
ponectin were developed and clinical effectiveness and usefulness are now under investigation. For development of radical therapies, low-molecular-weight
compounds are screened for AdipoR agonists.
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Adiponectin is a fat-derived hormone that appears to play
a crucial role in protecting against insulin resistance/diabetes
and atherosclerosis (Yamauchi et al., 2001, 2002; Fruebis
et al., 2001; Berg et al., 2001; Kubota et al., 2002; Maeda
et al., 2002). Decreased adiponectin levels are thought to play
a central role in type 2 diabetes and have been reported to be
the most powerful predictor of diabetes, as well as cardiovas-
cular disease, linked to obesity in humans (Kadowaki et al.,
2006; Shetty et al., 2009; Matsuzawa, 2010). In the past 10 years,
the receptors AdipoR1 and AdipoR2 were discovered and
cloned, which was the starting point of fundamental under-
standing of adiponectin actions. In fact, pivotal roles of AdipoR1
and AdipoR2 in pleiotropic adiponectin actions have been
demonstrated. Postreceptor signalingmechanisms downstream
of AdipoR1 and AdipoR2 have also been progressively eluci-
dated, albeit not completely.
As depicted in Figure 5, using DNA chips, we screened for
secreted molecules in WAT, the expressions of which were
increased in small adipocytes from insulin sensitive mice suchas heterozygous PPARg-deficient mice, and we found that
increased expression of adiponectin correlates with increased
insulin sensitivity in mouse models of altered insulin sensitivity.
Combination of these expression profiles and epidemiological
association studies between low adiponectin and clinical param-
eters, as well as functional analyses using transgenic or
knockout mice led to identification of adiponectin as a key mole-
cule of lifestyle-related disease such as diabetes. Then, AdipoR1
and AdipoR2were identified by expression cloning. Disruption of
AdipoR1 and AdipoR2 revealed that AdipoR1 and AdipoR2 are
required for specific binding of adiponectin and glucose-
lowering effects of adiponectin, indicating that AdipoR1 and
AdipoR2 are major adiponectin receptors in vivo. Moreover,
disruption of AdipoR revealed that adiponectin could activate
AMPK/SirT1/PGC-1 and PPARs via AdipoR. Interestingly,
PPARa agonists and angiotensin II receptor blocker (ARB)
increase AdipoR expression. Humanmutation analyses revealed
that HMW adiponectin is the more active form of the protein
and has a more relevant role in insulin sensitivity. Importantly,
PPARg agonists (TZDs and non-TZDs) and ARB increase totalCell Metabolism 17, February 5, 2013 ª2013 Elsevier Inc. 193
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Reviewand HMW adiponectin. For development of methods for diag-
nosis, methods for specific quantification of HMW adiponectin
were developed and clinical effectiveness and usefulness are
now under investigation. For development of radical therapies,
low-molecular-weight compounds are screened for AdipoR
agonists. Parallel to first-in-class drug development of low-
molecular-weight compounds targeted to AdipoR, the analysis
of 3D conformation of AdipoR is also under investigation.
Toward development of best-in-class drugs for lifestyle-related
diseases, AdipoR agonists are optimized based on three-dimen-
sional conformation of AdipoR agonists-AdipoR complex.
We believe that further work on AdipoRs should facilitate both
the understanding of the molecular mechanisms of adiponectin
actions and obesity-related diseases such as diabetes and
shortened life span, and also focus on the designing of antidia-
betic and antiaging drugs with AdipoR agonist as a target.
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